膦甲酸钠联合胸腺肽-α_1治疗重型肝炎的临床观察

Clinical observation of treatment of gravis hepatitis B with foscavir see foscarnet sodium and thymic peptide-α_1

目的 观察膦甲酸钠联合胸腺肽-α1治疗重型肝炎的疗效。方法 膦甲酸钠注射液250ml（内含膦甲酸钠3．0g），静滴2次／日，疗程4周；胸腺肽-α1 1．6mg／次，1次／隔日，皮下注射，共用12～14次。对照组仅用保肝、降酶、退黄及对症治疗。结果治疗后两组疗效比较在统计学上差异有显著性（P〈0．05）。结论 说明膦甲酸钠联合胸腺肽-α1治疗重型肝炎具有良好的效果，可延长生命，降低病死率。

Aim To observe the therapeutic result of gravis hepatitis B with the combination therapy of foscavir see foscarnet sodium and thymic peptide-α1. Method There are 12 gravis hepatitis B patients in this observation. After being confirmed that HBV actively replicating in these patients, we perform the antivirus therapy with the combination of Foscavir （ 3.0 grams, intravenous drop, twice a day ） and thymic peptide-α1（ 1.6 mg, subcutaneous injection, every other day） on the grounding therapy of hepatocyte protection. The course of treatment is 8 weeks. Result The observation indexes at pretherapy, at the end of 2, 4, 8 weeks have significant difference. Conclusion The combination therapy of gravis hepatitis B with foscavir and thymic peptide-α1 is effective, can prolong life and lower fatality rate.